N-acyl pyrimidine-biphenyl small molecules bind PD-L1, restore T cell activity and curb tumor growth in a syngeneic breast cancer model
- A series of N-acyl pyrimidine-biphenyl analogues was designed as small-molecule PD-L1 inhibitors; A6 and A12 were potent binders in a reporter assay.
- Molecular dynamics attributed A6's slight edge to persistent interaction with D122.
- A6 disrupted PD-1/PD-L1 binding in ELISA, restored T cell activity, boosted cytokine secretion and enhanced T cell-mediated tumor cell killing.
- In the syngeneic 4T1 model it suppressed tumor growth without systemic toxicity.
💡 Points Based on the abstract
Biphenyl cores are the familiar BMS-type PD-L1 pharmacophore, so novelty rides on the N-acyl pyrimidine. Those biphenyls induce PD-L1 dimerization, and the D122 story comes only from MD. I'd want a co-crystal or NMR, human versus mouse PD-L1 affinity (4T1 is murine), and a SPR KD with solubility data before trusting the potency ranking.